Does the halo count on temporal and axillary ultrasound predict time to relapse in giant cell arteritis?

"Disclosure statement : R.J.W. declares protocol development and oversight for Galapagos on behalf of his institution and speaker honoraria for Janssen (includes speakers bureau, symposia, and expert witness). S.L.M. reports consultancy on behalf of her institution for Roche/Chugai, Sanofi, AbbVie, AstraZeneca; investigator on clinical trials for Sanofi, GSK, Sparrow; speaking/lecturing on behalf of her institution for Roche/Chugai, Vifor and Pfizer; chief investigator on STERLING-PMR trial, funded by the National Institute for Health and Care Research (NIHR); patron of the charity PMRGCAuk. No personal remuneration was received for any of the above activities. Support was received from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend the ACR Convergence 2021 virtually. S.L.M. is supported in part by the NIHR Leeds Biomedical Research Centre. The views expressed in this article are those of the authors and not necessarily those of the NIHR, the NIHR Leeds Biomedical Research Centre, the National Health Service or the UK Department of Health and Social Care."

"Funding No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Disclosure statement: R.J.W. declares protocol development and oversight for Galapagos on behalf of his institution and speaker honoraria for Janssen (includes speakers bureau, symposia, and expert witness). S.L.M. reports consultancy on behalf of her institution for Roche/Chugai, Sanofi, AbbVie, AstraZeneca; investigator on clinical trials for Sanofi, GSK, Sparrow; speaking/lecturing on behalf of her institution for Roche/Chugai, Vifor and Pfizer; chief investigator on STERLING-PMR trial, funded by the National Institute for Health and Care Research (NIHR); patron of the charity PMRGCAuk. No personal remuneration was received for any of the above activities. Support was received from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend the ACR Convergence 2021 virtually. S.L.M. is supported in part by the NIHR Leeds Biomedical Research Centre. The views expressed in this article are those of the authors and not necessarily those of the NIHR, the NIHR Leeds Biomedical Research Centre, the National Health Service or the UK Department of Health and Social Care."